Openbookopenbook
Equity
StockUS listing USRVMDNASDAQHealthcareEarnings Deterioration

Revolution Medicines Inc(RVMD) Stock Analysis | Healthcare

USD --+0.00%
Reward46Moderate
Risk46Moderate
75%Data
Revenue down 95% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 44.29Bn
Reward Ratingⓘ46 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ46 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RVMD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Revolution Medicines Inc?

, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers.

AI Brief Pro

The brief on Revolution Medicines Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Revolution Medicines Inc?

, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 44.29B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (46)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

ONCLarge Cap / 40.5B market cap
BeiGene, Ltd.
Compare
ARGXLarge Cap / 57.2B market cap
argenx NV ADR
Compare
UCBJFLarge Cap / 58.1B market cap
UCB SA
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap44.29B
P/E RatioN/A
Dividend YieldN/A
Beta1.406
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
1120,000 shares
$18.0M
0
6-9months
10149,592 shares
$15.0M
0
9-12months
9183,792 shares
$12.4M
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.